Enzymatic assay for quantitative analysis of ( d )-2-hydroxyglutarate

Clicks: 266
ID: 117927
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #33 of 438 articles by views in acta neuropathologica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 438 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Levels of (d)-2-hydroxyglutarate [D2HG, (R)-2-hydroxyglutarate] are increased in some metabolic diseases and in neoplasms with mutations in the isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) genes. Determination of D2HG is of relevance to diagnosis and monitoring of disease. Standard detection methods of D2HG levels are liquid-chromatography–mass spectrometry or gas-chromatography–mass spectrometry. Here we present a rapid, inexpensive and sensitive enzymatic assay for the detection of D2HG levels. The assay is based on the conversion of D2HG to α-ketoglutarate (αKG) in the presence of the enzyme (d)-2-hydroxyglutarate dehydrogenase (HGDH) and nicotinamide adenine dinucleotide (NAD+). Determination of D2HG concentration is based on the detection of stoichiometrically generated NADH. The quantification limit of the enzymatic assay for D2HG in tumor tissue is 0.44 μM and in serum 2.77 μM. These limits enable detection of basal D2HG levels in human tumor tissues and serum without IDH mutations. Levels of D2HG in frozen and paraffin-embedded tumor tissues containing IDH mutations or in serum from acute myeloid leukemia patients with IDH mutations are significantly higher and can be easily identified with this assay. In conclusion, the assay presented is useful for differentiating basal from elevated D2HG levels in tumor tissue, serum, urine, cultured cells and culture supernatants.
Reference Key
balss2012actaenzymatic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jörg Balss;Stefan Pusch;Ann-Christin Beck;Christel Herold-Mende;Alwin Krämer;Christian Thiede;Wolfgang Buckel;Claus-Dieter Langhans;Jürgen G. Okun;Andreas von Deimling;Jörg Balss;Stefan Pusch;Ann-Christin Beck;Christel Herold-Mende;Alwin Krämer;Christian Thiede;Wolfgang Buckel;Claus-Dieter Langhans;Jürgen G. Okun;Andreas von Deimling;
Journal acta neuropathologica
Year 2012
DOI
doi:10.1007/s00401-012-1060-y
URL
https://link.springer.com/article/10.1007/s00401-012-1060-y
Keywords
pathology neurosciences

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.